[ad_1]
OSLO, Norway, Sept. 5, 2022 /PRNewswire/ — Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today announced the appointment of Stephen Worsley as Chief Business Officer (CBO).
Stephen Worsley is a pharmaceutical executive with over 25 years of experience in business development leadership, executing high-value strategic deals in the biopharmaceutical and drug discovery/development markets. As a business development executive, Varsley led the negotiation of transformative and award-winning technology and product partnerships for major medical companies.
Most recently, Stephen Worsley served as Vice President of Strategic Business Development at Redwood Biosciences/Catalent Pharma Services. Before that, he was CBO at Sutro Biopharma, Senior Vice President of Business Development at IndiMolecular and Vice President of Business Development at Peregrine Pharmaceuticals (dba Avid Pharma Services), among other roles in his career.
“As we plan continued progress towards achieving several important milestones in our development programs at Lytics, we are pleased to welcome Stephen Warslin to our management team at Lytics Biopharma; says Øystein Rekdal, CEO of Litix. “His extensive experience in business development will play a central role as we advance our line of immunostimulating drugs for cancer through a variety of strategic partnerships, acquisitions, equity investments, clinical collaborations and licensing transactions. There are many potential partner opportunities on the way to market.”
Stephens will begin his leadership role at Lytics on September 6. As the CBO position, he will join the Lytics executive team.
“I am very excited to be joining the Lytics team at an exciting time for the company, developing a very promising new immunotherapy drug for the treatment of cancer.” said Stephen Worsley.Interest in the platform is growing and clinical results will allow Lytics to consider more value for business development opportunities in the coming months and years..”
For more information please contact:
Ole Peter Nordby, ole.peter.nordby@lytixbiopharma.com
This information comes from Cision http://news.cision.com.
See original content: https://www.prnewswire.com/news-releases/lytix-biopharma-appoints-stephen-worsley-as-chief-business-officer-301617678.html
Source Lytix Biopharma AS
Company codes Oslo: Litics
[ad_2]
Source link
